Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/94960
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia |
Author: | Soverini, S. Branford, S. Nicolini, F.E. Talpaz, M. Deininger, M.W.N. Martinelli, G. Müller, M.C. Radich, J.P. Shah, N.P. |
Citation: | Leukemia Research, 2014; 38(1):10-20 |
Publisher: | Elsevier |
Issue Date: | 2014 |
ISSN: | 0145-2126 1873-5835 |
Statement of Responsibility: | Simona Soverini, Susan Branford, Franck E. Nicolini, Moshe Talpaz, Michael W.N. Deininger, Giovanni Martinelli, Martin C. Müller, Jerald P. Radich, Neil P. Shah |
Abstract: | Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T315I mutant has proven particularly difficult to target. This review summarizes the prevalence, impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detection of mutations. |
Keywords: | BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations |
Rights: | © 2013 The Authors. Published by Elsevier Ltd. Open access CC BY-NC-SA 3.0 |
DOI: | 10.1016/j.leukres.2013.09.011 |
Published version: | http://dx.doi.org/10.1016/j.leukres.2013.09.011 |
Appears in Collections: | Aurora harvest 7 Medicine publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
hdl_94960.pdf | Published version | 890.67 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.